N/A N=39

Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study

Prediabetic State

Bottom Line

View on ClinicalTrials.gov: NCT01099397 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2012

Primary outcome: Primary: Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose Tolerance Test [OGTT]), at Three Timepoints During Antihypertensive Treatment — 6; 8; 20; 18 participants — p=0.41

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: Oral glucose tolerance test (Other)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Florida
Primary completion: Dec 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose Tolerance Test [OGTT]), at Three Timepoints During Antihypertensive Treatment	6; 8; 20; 18; 7; 9	0.41

Summary

The purpose of this study is to determine if, in a subset of patients treated with a beta-blocker and diuretic, prediabetes is detectable to a greater extent through a 2-hour oral glucose tolerance test (OGTT) compared to fasting glucose measurement.

Eligibility Criteria

Inclusion Criteria

participation in PEAR:
an average seated home DBP > 85 mmHg and home SBP 5 minutes) clinic DBP between 90 mmHg and 110 mmHg and SBP 1.5 in men or 1.4 in women),
primary renal disease,
pregnancy or lactation,
liver enzymes > 2.5 upper limits of normal,
current treatment with NSAIDS,
COX2-inhibitors,
oral contraceptives or estrogen.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01099397). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.